Navigation Links
BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/6/2008

Presentation will be Web cast live

LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces today that on Tuesday, November 11, Mr. Gary Schmid, President and Chief Executive Officer of OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health, will present a review of ongoing pharmaceutical and nutraceutical activities at the Rodman and Renshaw 10th Annual Healthcare Conference to be held at the New York Palace Hotel in New York, NY. The presentation will take place at 4:55 P.M. ET.

The live Web cast of BELLUS Health's presentation (audio and visual) can be accessed at http://www.wsw.com/webcast/rrshq14/blus. A replay of the presentation will begin three (3) hours after the actual presentation time, and will be available until November 18, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1 877 680 4500 or visit the Web Site at http://www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.

CONTACT: Lise Hebert, Ph.D., Vice President, Corporate Communications, (450) 680-4572, lhebert@bellushealth.com


'/>"/>
SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. Penn study finds pro-death proteins required to regulate healthy immune function
7. UCLA researchers identify markers that may predict diabetes in still-healthy people
8. Air pollution linked to cardiovascular risk indices in healthy young adults
9. More proof needed of safety and quality of electronic personal health records
10. Health care incentive model offers collaborative approach
11. Loneliness is bad for your health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Scottsdale, Ariz. (PRWEB) , ... January 23, 2017 ... ... , recently analyzed statistics from 140 Buzzies users who entered metrics into the ... Serin's earlier clinical data. The new data showed that within just 30 seconds ...
(Date:1/24/2017)... ... ... The National Council of Alcoholism and Drug Dependence ( NCADD ), in ... designate the last full week of January as National Drug and Alcohol Facts Week. ... As a community, we can advocate for effective treatment, but also especially effective prevention ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... science companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed ... the globally recognized standard that establishes guidance for critical processes within translation, ...
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/23/2017)... Just two weeks remain until legal experts and senior industry leaders involved ... London to discuss the flow of pharmaceutical products post Brexit ... Trade 2017 . In the run up to the show, ... to read in the event download centre . ... Some of those confirmed include: ...
Breaking Medicine Technology: